Long-Term Outcomes of PCI for In-Stent Chronic Total Occlusion

0
0
0

Long-Term Outcomes of PCI for In-Stent Chronic Total Occlusion: What Patients and Doctors Need to Know

For people with coronary artery disease (CAD), in-stent chronic total occlusion (IS-CTO)—a complete blockage of a previously implanted stent that lasts more than 3 months—is one of the most challenging conditions to treat. Percutaneous coronary intervention (PCI), the minimally invasive procedure used to open blocked arteries, has grown more successful for IS-CTO thanks to new tools and techniques. But until recently, doctors didn’t have clear data on how well patients fared years after the procedure. A 2021 study from two leading Chinese cardiac centers—Beijing Anzhen Hospital and Fuwai Hospital—filled that gap, tracking nearly 500 IS-CTO patients for 30 months to uncover long-term risks and benefits.

What Is IS-CTO?

IS-CTO is a type of chronic total occlusion (CTO) that occurs inside or within 5 mm of a prior stent. Unlike “de novo” (new) CTOs—which block native coronary arteries—IS-CTO involves scar tissue, plaque, or blood clots building up in the stent itself. It’s estimated to account for 5–25% of all CTO cases treated with PCI, and it’s notoriously hard to fix because the stent’s metal structure complicates reopening the artery.

The Study: How It Was Done

Researchers retrospectively analyzed data from 474 IS-CTO patients who underwent PCI at their centers between 2015 and 2018. They split patients into two groups:

  • Successful PCI: 367 patients where the stent was fully opened (less than 30% residual narrowing, normal blood flow).
  • Failed PCI: 107 patients where the blockage couldn’t be opened.

All patients were followed for a median of 30 months (range: 17–42 months). The team tracked major adverse cardiac events (MACE), a composite of:

  • Recurrent angina (chest pain)
  • Heart attack in the target vessel
  • Heart failure
  • Cardiac death
  • Repeat revascularization (needing another PCI or bypass surgery for the same vessel, called TVR).

They also used statistical models to find which factors—like medication use or patient characteristics—predicted better outcomes.

Key Results: What Did They Find?

The study’s biggest takeaways fall into three categories: short-term relief, long-term challenges, and the power of medication.

1. Short-Term Benefits: Angina Relief and Fewer Emergencies

Successful PCI worked wonders for symptom relief in the first 1–2 years:

  • Angina-free patients: 80% of successful PCI patients had no chest pain at 1 year vs. 60% of failed PCI patients. By year 2, the gap narrowed but still favored successful PCI (73% vs. 60%).
  • MACE rates: Successful PCI patients were half as likely to have a major heart event in year 1 (20% vs. 40%) and 30% less likely in year 2 (28% vs. 41%).

These results align with what doctors see in practice: opening a blocked stent quickly eases ischemia (low blood flow to the heart), which reduces chest pain and emergency visits.

2. Long-Term Challenges: Reocclusion and Fading Benefits

By 30 months, the short-term wins faded:

  • MACE rates: No significant difference between successful (44.2%) and failed (45.3%) PCI groups.
  • Reocclusion: 28.5% of successful PCI patients had the stent close up again.
  • Repeat revascularization: 26.1% needed another procedure to open the same vessel.

In other words, nearly one in three patients lost the benefit of PCI over time—and one in four required a second intervention.

3. The Game-Changer: Longer Dual Antiplatelet Therapy (DAPT)

The most surprising finding? Patients who took DAPT (aspirin plus a second antiplatelet drug like clopidogrel or ticagrelor) for more than 18 months had:

  • 2.7x lower risk of repeat revascularization (TVR).
  • 1.9x lower risk of MACE (not caused by repeat procedures).

Crucially, longer DAPT didn’t lead to more major bleeding—one of the biggest fears with antiplatelet therapy.

What Does This Mean for Patients?

If you’ve had IS-CTO PCI:

  • Short-term win: Expect relief from angina for 1–2 years. This is a big quality-of-life boost if you’ve been struggling with chest pain.
  • Long-term plan: Don’t stop DAPT early. Even if you feel fine, staying on your medication for at least 18 months cuts your risk of repeat procedures and serious heart events. Talk to your doctor before making any changes.
  • Failed PCI?: Your long-term risk of MACE is similar to those who had successful PCI. But if angina persists, ask about CABG—this study found bypass surgery had a much lower MACE rate (13.6%) than either PCI group.

If you’re considering PCI:

  • Ask your doctor: Do I have disabling angina? Is there viable heart muscle at risk? PCI is most helpful for patients with severe symptoms or muscle that could be saved. For asymptomatic patients, medical therapy (statins, beta-blockers, ACE inhibitors) is often safer.

What Does This Mean for Doctors?

For clinicians, the study reinforces three key principles:

  1. Symptom relief matters—but it’s not everything: IS-CTO PCI is great for short-term angina, but long-term outcomes depend on more than just opening the stent.
  2. DAPT duration is non-negotiable: Extend DAPT to at least 18 months for IS-CTO patients. This simple step reduces reocclusion and MACE without increasing bleeding risk.
  3. Use IVUS more: The study found intravascular ultrasound (IVUS)—a tool that lets doctors see inside the stent—was underused. Past research shows IVUS-guided PCI cuts MACE risk by ensuring stents are placed correctly. Don’t skip this step for complex cases like IS-CTO.

Limitations to Keep in Mind

No study is perfect. This one had a few key flaws:

  • Retrospective design: Researchers looked back at existing data instead of assigning patients to treatments randomly. This can introduce bias (e.g., doctors might have chosen PCI for healthier patients).
  • Small sample: 474 patients is smaller than many CTO studies, so results may not apply to all populations.
  • Limited IVUS use: Only 5.7% of patients had IVUS, which could have affected outcomes.

Final Thoughts

For IS-CTO patients, the study sends a clear message: PCI helps with pain now, but DAPT keeps your heart healthy later. The short-term relief is real, but the long-term benefits depend on sticking to your medication and working with your doctor to manage risk factors like high cholesterol or blood pressure.

For doctors, it’s a reminder that technical success (opening the stent) isn’t enough—we need to focus on patient-centered outcomes: fewer symptoms, fewer repeat procedures, and longer, healthier lives.

The biggest takeaway? In IS-CTO care, patience and persistence pay off—for both patients and providers.

Study Details

This study was published in the Chinese Medical Journal (2021) by:

  • Ming-Lian Gong, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University.
  • Yi Mao, Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Science.
  • Jing-Hua Liu (corresponding author), Beijing Anzhen Hospital.

You can access the full study at: doi.org/10.1097/CM9.0000000000001289

Was this helpful?

0 / 0